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*Corresponding Author. E-mail: martinthan@xtra.co.nz.Volume 6Study objective: A 2-hour accelerated diagnostic pathway based on the Thrombolysis in Myocardial Infarction score,
ECG, and troponin measures (ADAPT-ADP) increased early discharge of patients with suspected acute myocardial
infarction presenting to the emergency department compared with standard care (from 11% to 19.3%). Observational
studies suggest that an accelerated diagnostic pathway using the Emergency Department Assessment of Chest Pain
Score (EDACS-ADP) may further increase this proportion. This trial tests for the existence and size of any beneﬁcial
effect of using the EDACS-ADP in routine clinical care.
Methods: This was a pragmatic randomized controlled trial of adults with suspected acute myocardial infarction,
comparing the ADAPT-ADP and the EDACS-ADP. The primary outcome was the proportion of patients discharged to
outpatient care within 6 hours of attendance, without subsequent major adverse cardiac event within 30 days.
Results: Five hundred ﬁfty-eight patients were recruited, 279 in each arm. Sixty-six patients (11.8%) had a major adverse
cardiac event within 30 days (ADAPT-ADP 29; EDACS-ADP 37); 11.1% more patients (95% conﬁdence interval 2.8% to
19.4%) were identiﬁed as low risk in EDACS-ADP (41.6%) than in ADAPT-ADP (30.5%). No low-risk patients had a major
adverse cardiac event within 30 days (0.0% [0.0% to 1.9%]). There was no difference in the primary outcome of proportion
discharged within 6 hours (EDACS-ADP 32.3%; ADAPT-ADP 34.4%; difference 2.1% [10.3% to 6.0%], P¼.65).
Conclusion: There was no difference in the proportion of patients discharged early despite more patients being
classiﬁed as low risk by the EDACS-ADP than the ADAPT-ADP. Both accelerated diagnostic pathways are effective
strategies for chest pain assessment and resulted in an increased rate of early discharges compared with previously
reported rates. [Ann Emerg Med. 2016;68:93-102.]
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Background and Importance
The diagnostic challenge of assessing patients presenting
to the emergency department (ED) with symptoms
suggestive of cardiac ischemia is to maintain high accuracy
for the rule-out of acute myocardial infarction without
unnecessary admission.1 The development of risk assessment
aids and accelerated diagnostic pathways has provided new
screening tools to improve the rate of early safe discharge to
outpatient care of patients with symptoms that suggest acute
myocardial infarction. An accelerated diagnostic pathway8, no. 1 : July 2016facilitates faster diagnostic decisions through blood sampling
at earlier points for cardiac troponin (cTn) level for some
patients stratiﬁed into a low-risk category with the pathway
(Figure 1). This allows clinicians to rapidly proceed to the
same “next step” in clinical management (such as cardiac
stress test, imaging, or discharge) as would have occurred
with a more prolonged time course for serial troponin level
testing to exclude acute myocardial infarction.
Most accelerated diagnostic pathways have been
evaluated only in observational studies.2-4 The ﬁndings of
observational research may overestimate the effect ofAnnals of Emergency Medicine 93
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What is already known on this topic
Several accelerated diagnostic protocols using high-
sensitivity troponins are challenging the traditional
process of ruling out acute myocardial infarction
during 8 to 24 hours.
What question this study addressed
This pragmatic clinical trial compared 2 such
protocols, the ADAPT-ADP and the EDACS-ADP,
to determine the proportion of patients discharged
without an adverse event, using each protocol.
What this study adds to our knowledge
The EDACS-ADP identiﬁed 11.8% more low-risk
patients (95% conﬁdence interval 2.8% to 19.4%)
than ADAPT-ADP; however, the proportion of all
discharged was not different (32.3% versus 34.4%).
No low-risk patients in either group had a major
adverse event.
How this is relevant to clinical practice
Regardless of protocol used, the patients considered
low risk were unlikely to have an adverse event. The
EDACS-ADP identiﬁed more patients but had the
same discharge rate as the ADAPT-ADP, raising the
concern that clinicians might not be acting on this
information.intervention. In contrast, pragmatic randomized controlled
trials (without strictly enforced procedures) enable new
accelerated diagnostic pathways to be compared with one
another or with current practice and provide an indicationA
Figure 1. Schematic illustrating earlier decisionmaking through ac
decision points. ACS, Acute coronary syndrome.
94 Annals of Emergency Medicineof clinician acceptance of a new process. They account for
the realities of medicine in a complex, busy environment,
including potential latency of staff education in achieving
acceptance and adoption of a new process.
Since the advent of cTns, only 1 randomized controlled
trial has assessed the ability of an accelerated diagnostic
pathway to hasten decisionmaking.5 This trial demonstrated
an increased rate of successful discharge to outpatient care
within 6 hours of presentation from a local baseline of
11.0% to 19.3% by using an accelerated diagnostic
pathway incorporating the Thrombolysis in Myocardial
Infarction (TIMI) score. To our knowledge, no randomized
controlled trials have incorporated the use of high-sensitivity
cardiac troponin assays either within an accelerated
diagnostic pathway or as part of the outcomes adjudication.
Although the TIMI risk score has been successfully
adapted for rule-out of acute coronary syndrome,5,6 it was
not designed to identify low-risk patients from a clinically
diverse ED population. We therefore developed the
Emergency Department Assessment of Chest Pain Score
(EDACS) speciﬁcally to identify patients presenting to the
ED with chest pain who were at low 30-day risk of a major
adverse cardiac event.7 EDACS was developed from 37
candidate variables in a derivation cohort of 1,974 patients in
the ED with possible cardiac ischemia. It combines clinical
variables identiﬁed as independent predictors for major
adverse cardiac events to identify a subgroup of patients who
are at low risk of such an event within 30 days (Table 1).
When combined with ECG and either contemporary or
high-sensitivity cTn results, this score forms part of an
accelerated diagnostic pathway (EDACS-ADP). In
derivation and validation cohorts using contemporary cTn,
the EDACS-ADP identiﬁed 45% and 51% of patients as low
risk, with a sensitivity for 30-day major adverse cardiac event
of 99% and 100%, respectively.7 This performance observedB
celerated diagnostic pathways. Light bulbs indicate clinical
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Table 1. Accelerated diagnostic pathway criteria for classiﬁcation patients as low risk.
Control ADP (ADAPT) Intervention ADP (EDACS)
No new ischemic ECG changes No new ischemic ECG changes
Negative troponin results at 0 and 2 h (hs-cTnI <16 ng/L for
women; hs-cTnI <34 ng/L for men)
Negative troponin results at 0 and 2 h (hs-cTnI <16 ng/L for women;
hs-cTnI <34 ng/L for men)
TIMI score¼0, where 1 point is given for each of the following
criteria (maximum TIMI score¼5):
(i) Age 65 y
(ii) 3 of the following 5 CAD risk factors: family history of
premature CAD (ie, at age <55 y, angina, MI, sudden cardiac
death without obvious cause), dyslipidemia, diabetes,
hypertension, current smoker
(iii) Known CAD (stenosis 50%)
(iv) Acetylsalicylic acid/aspirin use in the last 7 days
(v) Recent severe angina (eg, 2 events in last 24 h)
EDACS <16, where points are allocated according to the following:
(i) Age:
Age range, y
18–45
46–50
51–55
56–60
61–65
66–70
71–75
76–80
81–85
86
(ii) Only if age 18–50 y
Known CAD or 3 of the following 5 CAD risk factors: family history
of premature CAD (ie, at age <55 y, angina, MI, sudden cardiac
death without obvious cause), dyslipidemia, diabetes,
hypertension, current smoker
(iii) Symptoms
Diaphoresis (in association with pain*)
Pain* radiates to arm or shoulder
Pain* occurs or worsened with inspiration (pleuritic in nature)
Pain* reproduced by palpation
(iv) Sex
Male
Points
2
4
6
8
10
12
14
16
18
20
4
3
5
4
6
6
No red ﬂags (ie, patients with an unstable presentation comprising
abnormal vital signs or pain that is ongoing or in a crescendo
pattern should not be considered for the low-risk pathway)
No red ﬂags (ie, patients with an unstable presentation comprising
abnormal vital signs or pain that is ongoing or in a crescendo
pattern should not be considered for the low-risk pathway)
ADP, Accelerated diagnostic pathway; CAD, coronary artery disease.
*Pain that caused presentation to hospital.
Web calculators for the EDACS score available at: http://edaculator.adelaideemergencyphysicians.com and http://www.mdcalc.com/emergency-department-assessment-chest-
pain-score-edacs/
Than et al EDACS Versus ADAPT-ADPin the observational cohort required testing in a routine
clinical setting, using a prospective pragmatic randomized
controlled trial.
Goals of This Investigation
Clinicians do not always adhere to clinical pathways or
guidelines as expected, and it is important to determine
whether the EDACS-ADP would work within a clinical
pathway implemented into daily hospital care when the
attending clinician has ﬁnal decisionmaking authority. We
therefore designed a trial to test for the existence and size
of any beneﬁcial effect of using the EDACS-ADP in
routine clinical care. We tested the null hypothesis that
there was no difference in using the EDACS-ADP to
classify patients to low-risk category and early discharge
from the ED than using the modiﬁed ADAPT-ADP.MATERIALS AND METHODS
This study was a single-center, pragmatic, randomized,
clinical trial8 to compare the effectiveness of 2 acceleratedVolume 68, no. 1 : July 2016diagnostic pathways for the assessment of patients
presenting to the ED with possible cardiac ischemia. It
compared a control accelerated diagnostic pathway
(ADAPT-ADP5,9) and a novel accelerated diagnostic
pathway (EDACS-ADP7). The trial design was based
on the Consolidated Standards of Reporting Trials
(CONSORT) extension statement for pragmatic trials,8
and therefore the interventions allocated by randomization
were not strictly enforced. Although pathways for the
intervention and control arms were provided, the ﬁnal
clinical management decision was at the discretion of
the treating clinician. Research staff documented clinical
decisions but did not attempt to inﬂuence or intervene
in them. The research protocol was approved by the
New Zealand Health and Disability Ethics Committee.
Informed consent was obtained from all patients.Setting
Christchurch Hospital is an academic general hospital
and tertiary referral center servicing a regional populationAnnals of Emergency Medicine 95
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attendances per year. Patients self-present from the
community (by ambulance or own transport), but there are
also many referrals from primary care physicians. Local
guidelines for patients with possible acute myocardial
infarction require assessment by ED staff, including an
ECG, within 10 minutes of arrival to detect and fast-track
the management of patients with ST-segment elevation
myocardial infarction. The clinical experience of the
physicians ranges from intern through attending specialists.
Selection of Participants
Eligible patients were aged 18 years or older and presenting
acutely from the community to the ED with possible cardiac
symptoms suggestive of acute myocardial infarction for which
the attending clinician(s) intended to perform serial troponin
analysis to investigate for possible acute myocardial infarction.
In accordance with American Heart Association case
deﬁnitions, possible cardiac symptoms included the presence
of acute chest, epigastric, neck, jaw, or arm pain or discomfort
or pressure without apparent noncardiac source.10 Patients
were excluded if any of the following conditions were satisﬁed:
diagnosed ST-segment elevation myocardial infarction on
arrival; proven or likely noncoronary pathology as the cause of
symptoms; need for admission because of, or for further
investigation of, other medical conditions regardless of a
negative cTn result; previously enrolled in this study;
anticipated problem with follow-up (eg, resident outside New
Zealand); and unable to provide informed consent.
Enrollment was consecutive during the hours of the available
research nurse (normally 8 AM to 11 PM, 7 days a week).
The troponin assay used was the Abbott Architect
high-sensitivity troponin I (hs-cTnI; Abbot Diagnostics,
Chicago, IL). The 99th percentile is 16 ng/L for women and
34 ng/L for men, and the coefﬁcient of variation is less than
10% at 4.7 ng/L (permanufacturer’s package insert). For local
clinical patient management, troponin values above these sex-
speciﬁc 99th percentiles were reported as positive results.
Research nurses identiﬁed potential cases with both the
ED attendance screen and direct presence at the triage desk.
After consenting, randomization (1:1 allocation ratio)
used a sequential sealed envelope process. Study packs were
kept in a locked ﬁling cabinet. The numbered opaque
envelope containing the randomization allocation included
a number matched to the study packs. After consent, the
research nurse opened the next randomization envelope
and informed the patient’s clinician to which pathway
the patient was allocated. The randomization envelope
contained a paper copy of the allocated score, which, when
completed by the clinician (without inﬂuence from the
research staff), became part of the ofﬁcial patient record.96 Annals of Emergency MedicineThe randomization sequence arranged in permuted blocks
was generated by a statistician independent of patient
recruitment or outcome adjudication. Clinicians were
educated about the scores and background evidence for
the study, but not about the 6-hour primary outcome.
Interventions
In the control arm, patients followed the hospital’s
standard-care cardiac chest pain pathway incorporating the
ADAPT-ADP. On arrival, patients received an initial ECG,
and a blood samplewas obtained for theﬁrst hs-cTnI test. Risk
factors and symptoms were recorded and a modiﬁed TIMI
score was calculated by the clinician. If the initial hs-cTnI test
result was negative, there was no new ischemia observed by the
attending clinician(s) on the ﬁrst ECG, and the modiﬁed
TIMI score was 0, patients were moved to an ED or inpatient
ward observation area without ECG monitoring. New ECG
changeswere deﬁned as ST-segment depressionof at least 0.05
mV in 2 or more contiguous leads (including reciprocal
changes), T-wave inversion of at least 0.1 mV, or Q waves
greater than 30ms in width and 0.1 mV or greater in depth in
at least 2 contiguous leads. Changes that were present on
available preexisting ECGs were not deﬁned as new ischemia.
At 2 hours after the initial tests, blood was drawn for a second
hs-cTnI test. If all test results were negative, patients were
classiﬁed as low risk. These patients were then discharged and
scheduled for an outpatient stress test (typically exercise
treadmill test) unless the clinician decided that this was not
clinically indicated (eg, further cardiac testing was considered
inappropriate or had been recently performed). If any
diagnostic parameter was positive or the TIMI score was
greater than or equal to 1, patients were classiﬁed as not low
risk and were then admitted and managed according to the
usual clinical pathway.
In the experimental arm, patients received an initial ECG,
and a blood sample was obtained for the ﬁrst hs-cTnI test.
Risk factors and symptoms were recorded and the clinician
calculated the EDACS. If the initial hs-cTnI test result was
below the 99th percentile, there was no new ischemia (as
deﬁned above) observed on the ﬁrst ECG, and EDACS was
less than 16, patients were moved to an ED or ward
observation chair without ECGmonitoring. At 2 hours after
the initial tests, blood was drawn for a second hs-cTnI test. If
all test results were negative, patients were classiﬁed as low
risk, scheduled for an outpatient stress test (normally exercise
treadmill test), and discharged. If any diagnostic factor was
positive or the EDACS was greater than or equal to 16,
patients were not classiﬁed as low risk and their care was
managed according to the standard clinical pathway.
At Christchurch ED, clinical pathway forms exist to
standardize care in accordance with best practice. TheseVolume 68, no. 1 : July 2016
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expected to follow the pathway unless they can document
good clinical reasons not to. Patients presenting with
possible cardiac ischemia are entered onto a dedicated
“cardiac chest pain clinical pathway” (Canterbury District
Health Board ofﬁcial document C240005). This pathway
advises clinicians to identify patients at low risk and
suitable for early discharge, using the designated accelerated
diagnostic pathway (ADAPT or EDACS).
In summary, the only difference between the 2 study arms
was the tool used for risk scoring: modiﬁed TIMI versus
EDACS. In both pathways, sentinel ﬁndings indicative of
potential clinical instability and were described as red ﬂags.
These were either chest discomfort (thought to be possibly
cardiac in origin) that was ongoing or in a crescendo pattern,
or the presence of abnormal vital signs. The presence of a
red ﬂag meant that patients were classiﬁed as not low risk
irrespective of the risk assessment score.
Outcome Measures
The primary objective was to compare the effectiveness,
when applied to clinical practice, of an accelerated diagnostic
pathway within a clinical pathway that uses EDACS
against the standard accelerated diagnostic pathway, which
incorporates the TIMI score. The primary outcome was
successful discharge, deﬁned as discharge from the hospital
within 6 hours of ED arrival and without major adverse
cardiac event within 30 days.Major adverse cardiac event was
deﬁned as death (unless clearly noncardiac, eg, from trauma),
cardiac arrest, emergency revascularization procedure,
cardiogenic shock, ventricular arrhythmia needing
intervention, high-degree atrioventricular block needing
intervention, and acute myocardial infarction. All patients
were followed up with all 3 of the following approaches:
telephone contact, review of patient hospital notes, and
national death and health events search. (Patients in New
Zealandhave a unique alphanumeric identiﬁer for tracking all
hospital inpatient and outpatient events within the nation’s
health system.) Senior clinicians adjudicated for the presence
of any major adverse cardiac event and were blinded to study
group allocation. Adjudications were entered into a separate
database independent of all other trial data.The proportion of
patients identiﬁed as low risk was also compared.
Preliminary research predicted a 17% discharge rate at
6 hours in the control arm (experimental arm of the
former randomized controlled trial).5 It was considered that
if in the experimental arm at least 30% of patients were
successfully discharged, then this proportion would
represent a meaningful effect on clinical practice. This
study was powered to detect a 13% difference between the
successful early discharge rates, with a b¼.10 (90% power)Volume 68, no. 1 : July 2016and a 2-tailed a¼.05. This required recruitment of 265
patients in each arm and 530 patients in total. Blinding of
patients and clinical staff was not clinically possible.
Primary Data Analysis
The unit of analysis was patient and the primary
outcome compared randomized groups with a c2 test.
An adjusted comparison of the primary outcome was also
undertaken, which included any baseline measure, not part
of the modiﬁed TIMI or EDACS scores, in which there
was baseline imbalance between control and experimental
groups. The analysis used a multiple logistic regression and
the results are presented as adjusted odds ratios with the
95% conﬁdence intervals. The primary analysis was
undertaken on an intention-to-treat basis. All statistical
analysis was performed in R (version 3.1.0).11RESULTS
Characteristics of Study Subjects
We randomized 560 patients from June 26, 2013, to July
30, 2014. Two patients later withdrew consent, leaving
558 for the intention-to-treat analysis (Figure 2). There were
279 patients in each arm. The cohort was largely men (61%),
of New Zealand European ethnicity (76%), and with a mean
age of 58.7 years (Table 2). Patients presented at a median of
3.0 hours (interquartile range 1.5 to 7.8 hours) after symptom
onset. Sixty-six of 558 patients (11.8%) had a major adverse
cardiac event within 30 days (Table 3). All mortality events
and all hospital admission events were available for review for
all patients within the 30-day follow-up period from
Christchurch hospital inpatient data and the national health
event tracking system, which tracks all health events within
New Zealand. Additionally, 516 participants (97.7%) were
contacted by telephone or returned a questionnaire.
The EDACS-ADP classiﬁed 15.4% more patients as low
risk than the ADAPT-ADP (47.7% [n¼133] versus 32.3%
[n¼90]; difference 15.4% [95% conﬁdence interval 7.0% to
23.8%]). After reassignment of some patients to “not low
risk” because of the presence of clinical red ﬂags, 11.1%
more patients (95% conﬁdence interval 2.8% to 19.4%)
were classiﬁed as low risk by the experimental accelerated
diagnostic pathway (41.6%; n¼116) than by the control
accelerated diagnostic pathway (30.5%; n¼85) (see also
Figure E1, available online at http://www.annemergmed.
com). Eighty-ﬁve percent of low-risk patients had a stress test
within 3 days of ED presentation.
Main Results
There was no difference in the overall proportion
of patients successfully discharged (without majorAnnals of Emergency Medicine 97
*Randomized
n=560
eg, overseas resident)
eg, delayed decision,
Figure 2. CONSORT diagram of patient ﬂow and numbers. *Some patients met multiple exclusion criteria.
EDACS Versus ADAPT-ADP Than et aladverse cardiac event within 30 days) within 6 hours
(EDACS-ADP arm 90 [32.3%] versus ADAPT-ADP arm
96 [34.4%]; difference 2.1% [10.3% to 6.0%], P¼.65)
(Table 3).Table 2. Baseline characteristics.*
Variable Total Cohort (n[558) Co
Age, y 58.7 (11.9)
Women 218 (39.1)
Weight, kg 86.3 (18.7)
Body mass index, kg/m2 29.0 (5.6)
Ethnicity
Asian 14 (2.5)
Maori 21 (3.8)
New Zealand European 423 (75.8)
New Zealand European and Maori 1 (0.2)
Paciﬁc Islander 9 (1.6)
Other European 46 (8.2)
Other 34 (6.1)
Not stated 12 (2.2)
Risk factors and history
Hypertension 290 (52.0)
Dyslipidemia 284 (50.9)
Diabetes 78 (14.0)
Current smoker 84 (15.1)
Family history of ischemic heart disease 199 (35.7)
Previous angina 160 (28.7)
Previous myocardial infarction 130 (23.3)
Previous peripheral vascular disease 32 (5.7)
Previous percutaneous coronary intervention
or coronary artery bypass graft
153 (27.4)
Previous ischemic heart disease 236 (42.3)
Previous cardiovascular disease or transient
ischemic attack
33 (5.9)
*Data are presented as No. (%) or mean (SD) or median (lower quartile–upper quartile).
98 Annals of Emergency MedicineThere was no difference in the proportion of patients
classiﬁed as low risk and successfully discharged within 6
hours (EDACS-ADP arm 73 [26.2%] versus ADAPT-ADP
arm 64 [22.9%]) (Table 3). Of the 43 of 279 low-riskntrol ADP (ADAPT) (n[279) Experimental ADP (EDACS) (n[279)
57.8 (12.0) 59.6 (11.8)
105 (37.8) 113 (40.4)
86.2 (18.8) 86.3 (18.6)
29.1 (5.4) 29.0 (5.9)
9 (3.2) 5 (1.8)
13 (4.7) 8 (2.9)
210 (75.5) 213 (76.3)
1 (0.4) 0
2 (0.7) 7 (2.5)
16 (5.7) 30 (10.8)
20 (7.2) 11 (3.9)
7 (2.5) 5 (1.8)
143 (51.4) 147 (52.5)
145 (52.2) 139 (49.6)
34 (12.2) 44 (15.7)
41 (14.7) 43 (15.4)
103 (37.1) 96 (34.3)
75 (27.0) 85 (30.4)
55 (19.8) 75 (26.8)
13 (4.7) 19 (6.8)
68 (24.5) 85 (30.4)
120 (43.2) 116 (41.4)
20 (7.2) 13 (4.6)
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Table 3. Outcomes.
Outcome
Total Cohort
(n[558) (%)
Control ADP (ADAPT)
(n[279) (%)
Experimental ADP (EDACS)
(n[279) (%)
Difference, %
(95% CI)
Negative ECG and troponin results, and
either TIMI score 0 or EDACS <16
223 (38.6) 90 (32.3) 133 (47.7) 15.4 (7.0 to 23.8)
Negative ECG and troponin results, and TIMI
score 0 or EDACS <16 and no red ﬂag (low
risk)
201 (34.8) 85 (30.5) 116 (41.6) 11.1 (2.8 to 19.4)
Low-risk patients successfully discharged
within 6 h*
137 (24.6) 64 (22.9) 73 (26.2) 3.2 (–4.3 to 10.7)
Primary outcome: patients successfully
discharged within 6 h†
186 (33.3) 96 (34.4) 90 (32.3) –2.1 (–10.3 to 6.0) P¼.65
Diagnoses during initial presentation (all in
non–low-risk patients)
STEMI‡ 5 (0.9) 3 (1.1) 2 (0.7) –0.4 (–1.6 to 2.3)
NSTEMI 60 (10.8) 26 (9.3) 34 (12.2) 2.9 (–8.4 to 2.6)
Unstable angina 32 (5.7) 12 (4.3) 20 (7.2) 2.9 (–7.1 to 1.3)
Total patients with ACS diagnosis 97 (17.4) 41 (14.7) 56 (20.1) 5.4 (–12 to 1.3)
Emergency revascularization 3 (0.5) 2 (0.7) 1 (0.4) –0.4 (–1.2 to 1.9)
Death 1 (0.2) 1 (0.4) 0 –0.4 (–0.7 to 1.4)
Total patients with a MACE 65 (11.6) 29 (10.4) 36 (12.9) 2.5 (–8.2 to 3.2)
Additional diagnoses during readmissions
during 30 days after index presentation
(all in non–low-risk patients)
STEMI 1 (0.2) 1 (0.4) 0 –0.4 (–0.7 to 1.4)
NSTEMI 2 (0.4) 0 2 (0.7) 0.7 (–2.1 to 0.6)
Total patients with a MACE 3 (0.5) 1 (0.4) 2 (0.7) 0.4 (–1.9 to 1.2)
Total patients with a MACE within 30 days of
presentation (from index presentation or
readmission)
66 (11.8) 29 (10.4) 37 (13.3) 2.9 (–8.6 to 2.8)
CI, Conﬁdence interval; STEMI, ST-segment elevation myocardial infarction; MACE, major adverse cardiac event.
*Negative index test result (negative ECG result, negative 0- and 2-h troponin result, score <threshold, no red ﬂags) and no MACE event within 30 days of presentation, and
medical decision to discharge home made within 6 hours of ED presentation.
†Negative index test result (negative ECG result, negative 0- and 2-h troponin result) and no MACE event within 30 days of presentation, and medical decision to discharge home
made within 6 hours of ED presentation.
‡Diagnosed after initial assessment on presentation in which patients with initial STEMI were excluded.
Than et al EDACS Versus ADAPT-ADPpatients (15.4%) in the experimental accelerated diagnostic
pathway not discharged within 6 hours, most (28 of 43;
65.1%) had TIMI scores greater than or equal to 1, with 15
subsequently discharged within 12 hours and no major
adverse cardiac event occurring within 30 days. Among
patients classiﬁed as low risk with the EDACS-ADP who
were not discharged within 6 hours, 17 of 43 (39.5%) had a
previous acute myocardial infarction, percutaneous coronary
intervention or coronary artery bypass graft, whereas only 5
of 73 (6.85%) of those discharged within 6 hours had had
either of those conditions (P<.001). Of the 21 of 279 low-
risk patients (7.5%) in the ADAPT-ADP arm not
successfully discharged within 6 hours, 11 were discharged
within 12 hours, with no major adverse cardiac event within
30 days. Overall, no patients classiﬁed as low risk in either
arm had a major adverse cardiac event within 30 days
(0.0% [0.0% to 1.9%]).
DISCUSSION
To our knowledge, this pragmatic randomized controlled
trial is the ﬁrst evaluating 2 accelerated diagnostic pathwaysVolume 68, no. 1 : July 2016designed to facilitate the speed of discharge decisions. It
directly compared the ADAPT-ADP,which is based on a risk
model developed for use in high-risk populations, with
the EDACS-ADP, speciﬁcally developed to improve the
identiﬁcation of ED patients at low risk of short-term
adverse events. Consistent with the results of the previous
development and validation studies for the EDACS-ADP,7
our study found that a clinically important, larger proportion
of patients were categorized as low risk by the EDACS-ADP
than the control ADAPT-ADP. However, the primary
outcome of the rate of safe discharge to outpatient care
within 6 hours was similar in both arms.
A possible contributor to the null result of this
randomized controlled trial is that the proportion of
patients discharged within 6 hours in the ADAPT-ADP
(34.4%) arm was much greater than in the ADAPT arm of
a previous randomized controlled trial at the same hospital
(18.3%) on which the power calculations had been based,
despite a similar proportion of patients being classiﬁed as
low risk with the ADAPT-ADP in the current and
previous trials (32.3% versus 35.0%). Another contributorAnnals of Emergency Medicine 99
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early patients with known coronary artery disease (ie,
previous acute myocardial infarction or revascularization
procedure); such patients represented 39.5% of cases
designated as low risk but not discharged early in the
EDACS-ADP arm.
Both the EDACS-ADP and ADAPT-ADP safe discharge
rates were greater than in the previous randomized controlled
trial.5 The 15.1% absolute increase in early discharge in the
ADAPT-ADP arms between studies partly resulted from
improved clinician adherence to the ADAPT-ADP and
suggested that clinicians take time to adjust to using a new
diagnostic pathway. In the ﬁrst randomized controlled trial, a
large proportion (13%) of patients (in the then-experimental
ADAPT-ADP arm) were classiﬁed as low risk but still
admitted to the hospital (without subsequent ACS). In
this study, only 7.5% of patients in the ADAPT-ADP arm
were classiﬁed as low risk and admitted to the hospital,
demonstrating improved compliance, whereas the equivalent
rate for the EDACS-ADPwas 15%. The early discharge rates
in this study demonstrate a noticeable change from the
baseline rate determined from analysis of the Christchurch
cohort of the original ADAPT observational study, which
was 5.4%.12 This demonstrates that there has been a
striking change in clinical practice. The EDACS-ADP was
implemented locally within 3 months of completion of this
trial (and the release of the preliminary safety analysis) at
the request of clinical staff (current pathway, Appendix E1,
available online at http://www.annemergmed.com). This
was straightforward because the embedding of the research
into the patient record meant that the only change required
was the removal of the TIMI score. The pathways have now
been implemented in 25 of 26 health regions inNewZealand
and also widely in Australia.
To our knowledge, this study provides the ﬁrst evidence
of the effective use of the EDACS-ADP in a clinical setting.
The trial was conducted without enforcement of the
allocated study protocol so that a realistic measurement of
the effect of introducing the pathway could be obtained.
The EDACS-ADP identiﬁed considerably more patients
as low risk than the ADAPT-ADP, consistent with the
results from observational research.1,7 Although it may be
expected that classifying more patients as low risk with the
EDACS-ADP would lead to increased early discharge,
clinicians do not always follow pathways or act as expected.
For example, a study of 117 EDs found that international
evidence-based guidelines for the investigation of pulmonary
embolism were not followed for 47% of patients.13 This
phenomenon likely affected the primary outcome. It is
possible that over time, with greater clinician acceptance
of the protocol and robust clinical education, a higher100 Annals of Emergency Medicineearly-discharge rate may be achieved with the EDACS-ADP.
This also emphasizes the point that beneﬁts of diagnostic
strategies predicted by observational studies are often not
fully achieved when implemented into practice.
The absence of adverse cardiac events among patients
categorized as low risk in either pathway offers some
reassurance about the safety of these investigative approaches
when implemented into actual patient management. In
comparison to observational studies of other pathways, a
validation of the New Vancouver Chest Pain Rule, using
high-sensitivity troponin as the only biomarker, reported
99.1% sensitivity for ACS in 13.0% of patients identiﬁed as
low risk.14 In 3 recent validation studies of the HEART
(History, ECG, Age, Risk factors and Troponin) score, the
proportion of low-risk patients (score 0 to 3) was 20.1% to
36.4%, with a sensitivity of 96.3% to 99.1%. A validation of
the North American Chest Pain Rule classiﬁed 4.4% of
patients as low risk, with a sensitivity of 100%.15 It remains
unclear how these strategies will perform in actual clinical
practice.
To our knowledge, this is the ﬁrst randomized
controlled trial that uses only a high-sensitivity cardiac
troponin assay and also sex-speciﬁc cutoffs within a clinical
pathway. It appears that neither change has had an adverse
effect on the proportion of patients categorized as low risk.
This is consistent with our experience of using this
particular hs-cTnI assay in our institution for almost 3
years, during which time there has not been any noticeable
increase in troponin I positivity rate (in >20,000 cases)
compared with that for the previously used contemporary
assay. This is important because, based on experience with
high-sensitivity troponin T, concern has been raised that
the use of hs-cTnI will also lead to increased positive
troponin results, which would lead to a lower proportion of
low-risk patients than predicted from previous studies.16,17
A recent prospective cohort study also suggested that
increased positivity may not occur with this hs-cTnI
assay.18 EDACS was developed with 2 contemporary
(nonhigh sensitivity) assays and was then also validated
with these assays. Thus, the ADAPT and EDACS
accelerated diagnostic pathways have now been shown to
work effectively with both contemporary and high-
sensitivity troponin assays. Lower cutoffs for women might
have had a similar effect.19 The proportion of patients
classiﬁed here as low risk either with or without
incorporating red ﬂags (41.6% and 47.7%, respectively) is
similar to that reported in the EDACS-ADP derivation and
validation cohorts (42.2% and 51.3%, respectively) using
contemporary nonhigh-sensitivity troponin assays. The
incorporation of high-sensitivity cardiac troponin within
the outcome adjudication in this and future trials isVolume 68, no. 1 : July 2016
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possibly true-positive cases otherwise missed with
contemporary troponin assays. This would be reﬂected in a
lower estimated sensitivity and negative predictive value for
the accelerated diagnostic pathway.
This was a single-center trial, which may limit the
generalizability of the ﬁndings. Comparing the EDACS-
ADP with an existing accelerated diagnostic pathway
made demonstrating a difference between arms harder to
achieve (than a comparison with no accelerated diagnostic
pathway). However, because the purpose of this trial was
to determine whether it was possible to improve on an
existing risk model with a “ﬁt-for-purpose” improved risk
model, we believe this comparison is appropriate. We
chose a pragmatic trial design to help clinicians and health
policymakers to judge the effectiveness of the EDACS-
ADP in actual clinical care. Therefore, selection criteria
were broad and reﬂected routine clinical practice.8 The
interventional nature of the trial meant that some late acute
myocardial infarctions may have been missed despite
follow-up because there was no delayed measurement of
troponin in some patients. Overall, only 3 patients had a
prevalent major adverse cardiac event during follow-up,
and although there were no occurrences of major adverse
cardiac event in patients discharged early, this study was
not powered to compare safety between the intervention
and control groups because the numbers of patients
required to prove noninferiority for safety compared with
an existing diagnostic strategy are very large, and this is
particularly true in this setting with a predicted adverse
event rate of 0% to 1%. We calculated that to power the
study for safety would require a sample size of more than
7,500. We believed that such a large trial was not merited
with such a low expectation of detecting a difference.
The pragmatic trial design may have also inﬂuenced the
primary outcome because there was no enforcement to
randomization allocation or risk categorization. Clinicians
may have been inﬂuenced by participation in the trial
situation, which may have affected their decisions for
either, or both, study groups. In the future, additional
insights about accelerated diagnostic pathway pathways
may be provided by other study designs (eg, a stepped-
wedge cluster randomized controlled trial).
In summary, this trial conﬁrmed that the EDACS-ADP
classiﬁes a larger proportion of patients presenting with
symptoms suggestive of cardiac ischemia as low risk and
eligible for early discharge than the modiﬁed TIMI
accelerated diagnostic pathway. This did not translate into
more early discharges, which may reﬂect delay in achieving
full clinician familiarity and adherence to the pathway. Our
ﬁnding that both accelerated diagnostic pathways facilitatedVolume 68, no. 1 : July 2016more early discharges than the previous nonaccelerated
pathway demonstrates that accelerated diagnostic pathways
can be effective strategies for patient assessment and
supports wider implementation.
The authors acknowledge the many research nurses
involved in recruitment and data collection, members of the
Christchurch Heart Institute Lorraine Skelton, RN, ADN, for
supervising the nurses, Judy Heslop, NZCS, for supervising
sample collection, and Barbara Neame, BIT, for maintaining
the database.
Supervising editor: Judd E. Hollander, MD
Author afﬁliations: From the Christchurch Hospital, Christchurch,
New Zealand (Than, Pickering, Aldous, Ardagh, Deely, Florkowski,
George, Hamilton, Jardine, Troughton, van Wyk, Young, Bannister);
University of Otago, Christchurch, New Zealand (Pickering,
Frampton, Richards, Florkowski, George, Jardine, Troughton); the
Royal Brisbane and Women’s Hospital, Herston, and the University
of Technology, Brisbane, Queensland, Australia (Cullen); the Baylor
College of Medicine, Houston, TX (Peacock); Mayo Clinic,
Rochester, MN (Jaffe); the University of Shefﬁeld, United Kingdom
(Goodacre); the National University of Singapore, Singapore
(Richards); and the University of Notre Dame, Sydney Campus, and
the National Health and Medical Research Council Clinical Trials,
New South Wales, Australia (Lord).
Author contributions: MPT, SJA, LC, CMAF, WFP, ASJ, SWG, AMR,
MAW, JMD, CMF, PG, GJH, DLJ, RWT, and SJL contributed to the
study design; MPT, JWP, SJA, LC, CMAF, WFP, ASJ, SWG, AMR,
MWA, CMF, PG, RWT, PvW, JMY, LB, and SJL contributed to the
analysis and interpretation. MPT, JWP, LC, EP, JMD, and SJL
contributed to the drafting of the article. All authors provided
critical revision of the article. MPT takes responsibility for the
paper as a whole.
Funding and support: By Annals policy, all authors are required to
disclose any and all commercial, ﬁnancial, and other relationships
in any way related to the subject of this article as per ICMJE conﬂict
of interest guidelines (see www.icmje.org). The authors have stated
that no such relationships exist. The trial was funded by the Health
Research Council of New Zealand (grant 12-249).
Publication dates: Received for publication October 20, 2015.
Revision received December 23, 2015. Accepted for publication
December 31, 2015. Available online March 2, 2016.
Trial registration number: ACTRN12613000745741
REFERENCES
1. Than MP, Herbert M, Flaws D, et al. What is an acceptable risk of major
adverse cardiac event in chest pain patients soon after discharge from
the emergency department? a clinical survey. Int J Cardiol.
2013;166:752-754.
2. Hess EP, Brison RJ, Perry JJ, et al. Development of a clinical prediction
rule for 30-day cardiac events in emergency department patients with
chest pain and possible acute coronary syndrome. Ann Emerg Med.
2012;59:115-125.e1.
3. Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value
of the HEART score. Neth Heart J. 2008;16:191-196.Annals of Emergency Medicine 101
EDACS Versus ADAPT-ADP Than et al4. Six AJ, Cullen L, Backus BE, et al. The HEART score for the assessment
of patients with chest pain in the emergency department. Crit Pathw
Cardiol. 2013;12:121-126.
5. Than MP, Aldous S, Lord SJ, et al. A 2-hour diagnostic protocol for
possible cardiac chest pain in the emergency department: a
randomized clinical trial. JAMA Intern Med. 2014;174:51-58.
6. Kelly A-M, Klim S. Prospective external validation of an accelerated
(2-h) acute coronary syndrome rule-out process using a contemporary
troponin assay. Int J Emerg Med. 2014;7:42.
7. Than MP, Flaws D, Sanders S, et al. Development and validation of
the Emergency Department Assessment of Chest Pain Score and 2 h
accelerated diagnostic protocol. Emerg Med Australas. 2014;26:
34-44.
8. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of
pragmatic trials: an extension of the CONSORT statement. BMJ.
2008;337:a2390.
9. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for
unstable angina/non-ST elevation MI: a method for prognostication
and therapeutic decision making. JAMA. 2000;284:835-842.
10. Luepker RV, Apple FS, Christenson RH, et al. Case deﬁnitions for acute
coronary heart disease in epidemiology and clinical research studies: a
statement from the AHA Council on Epidemiology and Prevention; AHA
Statistics Committee; World Heart Federation Council on Epidemiology
and Prevention; the European Society of Cardiology Working Group on
Epidemiology and Prevention; Centers for Disease Control and
Prevention; and the National Heart, Lung, and Blood Institute.
Circulation. 2003;108:2543-2549.Annals’ Impa
Impact Factor score, one of many metrics
of the frequency with which the average
over a given per
Annals’ Impact Factor rose to an a
Annals’ score ranks #1 out of 25 jo
102 Annals of Emergency Medicine11. RCoreTeam.R:a languageandenvironment for statistical computing. April
2014. Available at: http://www.R-project.org/. Accessed August 14, 2015.
12. Than MP, Cullen L, Aldous S, et al. 2-Hour accelerated diagnostic
protocol to assess patients with chest pain symptoms using
contemporary troponins as the only biomarker: the ADAPT trial. J Am
Coll Cardiol. 2012;59:2091-2098.
13. Roy P-M, Meyer G, Vielle B, et al. Appropriateness of diagnostic
management and outcomes of suspected pulmonary embolism. Ann
Intern Med. 2006;144:157-164.
14. Cullen L, Greenslade JH, Than MP, et al. The new Vancouver Chest Pain
Rule using troponin as the only biomarker: an external validation study.
Am J Emerg Med. 2014;32:129-134.
15. Mahler SA, Miller CD, Hollander JE, et al. Identifying patients for early
discharge: performance of decision rules among patients with acute
chest pain. Int J Cardiol. 2013;168:795-802.
16. de Lemos JA. Increasingly sensitive assays for cardiac troponins: a
review. JAMA. 2013;309:2262-2269.
17. Korley FK, Jaffe AS. Preparing the United States for high-sensitivity
cardiac troponin assays. J Am Coll Cardiol. 2013;61:1753-1758.
18. Sandoval Y, Smith SW, Schulz KM, et al. Diagnosis of type 1 and type 2
myocardial infarction using a high-sensitivity cardiac troponin I assay
with sex-speciﬁc 99th percentiles based on the third universal
deﬁnition of myocardial infarction classiﬁcation system. Clin Chem.
2015;61:657-663.
19. Shah ASV, Grifﬁths M, Lee KK, et al. High sensitivity cardiac troponin
and the under-diagnosis of myocardial infarction in women:
prospective cohort study. BMJ. 2015;350:g7873.ct Factor
of a journal’s inﬂuence, is a measure
article in a journal has been cited
iod of time.
ll-time high this year, to 4.695.
urnals in emergency medicine.
Volume 68, no. 1 : July 2016
Figure E1. Flowcharts of pathways followed by patients in each arm of the study. *Three Control-ADP patients had positive ECG
results and 2 EDACS-ADP patients had positive ECG results (1 with an increased troponin level), and therefore they did not meet the
ret
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